Molbio Diagnostics IPO
Molbio Diagnostics IPO is priced at ₹768–₹807 per share with an issue size of ₹939.7 crore. The IPO opens on Aug 10, 2026 and closes on Aug 12, 2026, with a lot size of 18 shares and a minimum investment of ₹14,526.
Molbio Diagnostics Limited IPO
- IPO Dates
- Aug 10, 2026 – Aug 12, 2026
- Price band
- ₹768-807 per equity share
- Minimum Investment
- ₹14,526
- Issue size
- ₹939.7 Cr
- Lot size
- 18
- Allotment Date
- Aug 13, 2026
- Listing
- Aug 17, 2026
- Listing At
- BSE, NSE
IPO timeline
-
Aug 10, 2026
Open Date
Completed
-
Aug 12, 2026
Close Date
Current
-
Aug 13, 2026
Allotment Date
Upcoming
-
Aug 17, 2026
Listing Date
Upcoming
Unofficial pre-listing indicator
Molbio Diagnostics IPO GMP Today: ₹134
Molbio Diagnostics IPO GMP today is ₹134 per share (a 17% premium over the ₹807 upper price band) as of 12 Aug 2026, 1:30 PM IST. The indicative listing price is ₹941 (₹807 upper price band + ₹134 GMP). GMP fell ₹7 from the previous recorded quote.
- Current GMP
- ₹134
- GMP percentage
- 17%
- Upper price band
- ₹807
- Indicative listing price
- ₹941
During the recorded period, Molbio Diagnostics IPO GMP ranged from ₹50 to ₹180. The latest GMP is ₹134, down from ₹141.
Molbio Diagnostics IPO GMP trend (day-wise) 48 observations
| Date & time | GMP | Change | GMP % | Indicative price |
|---|---|---|---|---|
| ₹134 | −₹7 | 17% | ₹941 | |
| ₹141 | ₹0 | 17% | ₹948 | |
| ₹141 | +₹1 | 17% | ₹948 | |
| ₹140 | +₹6 | 17% | ₹947 | |
| ₹134 | +₹12 | 17% | ₹941 | |
| ₹122 | ₹0 | 15% | ₹929 | |
| ₹122 | ₹0 | 15% | ₹929 | |
| ₹122 | +₹4 | 15% | ₹929 | |
| ₹118 | +₹4 | 15% | ₹925 | |
| ₹114 | +₹1 | 14% | ₹921 |
Molbio Diagnostics IPO Live Subscription Details
View Subscription DetailsMolbio Diagnostics IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.
Last updated:Molbio Diagnostics IPO Essentials
Molbio Diagnostics IPO Details
Molbio Diagnostics IPO is priced at ₹768-807 per share with a total issue size of 939.7 crore. The IPO has a lot size of 18 shares and will be listed on BSE and NSE.
- Issue price
- ₹768-807 per equity share
- Lot size
- 18 shares
- Face value
- ₹1 Per Equity Share
- Issue size
- ₹939 Crores
- Total issue size
- 1,16,46,246 shares
(aggregating up to ₹939.7 crore) - Fresh issue
- 24,80,246 shares
(aggregating up to ₹200 crore) - Offer for sale (OFS)
- 91,66,000 shares
(aggregating up to ₹739.7 crore) - Retail Portion
- 35%
- Listing at
- BSE, NSE
- Listing date
- Registrar
- Kfin Technologies Ltd.
- Lead manager
-
Kotak Mahindra Capital Co.Ltd.,, IIFL Capital Services Ltd.,, Jefferies India Pvt.Ltd.,, Motilal Oswal Investment Advisors Ltd.
Market Lot Size
Investors can bid for a minimum of 18 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 18 | ₹14,526 |
| Retail(max) | 13 | 234 | ₹1,88,838 |
| sHNI(min) | 14 | 252 | ₹2,03,364 |
| sHNI(max) | 68 | 1,224 | ₹9,87,768 |
| bHNI(min) | 69 | 1,242 | ₹10,02,294 |
Molbio Diagnostics IPO Reservation
Molbio Diagnostics IPO reservation details show category-wise allocation of shares. Out of the total 11646246 shares, approximately 19.96% are reserved for QIB, 14.97% for NII, 34.94% for retail investors, 0.18% for employees, and 29.95% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 3487717 (29.95%) | |
| QIB Shares Offered | 2325146 (19.96%) | |
| NII (HNI) Shares Offered | 1743860 (14.97%) | |
| bHNI > ₹10L | 1162574 (10%) | 4613 |
| sHNI < ₹10L | 581286 (5%) | 2307 |
| Retail Shares Offered | 4069005 (34.94%) | 2,26,056 |
| Employee Shares Offered | 20520 (0.18%) | |
| Total Shares Offered | 11646246 (100%) |
Molbio Diagnostics IPO Analytics
Molbio Diagnostics IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Molbio Diagnostics IPO Subscription Status
Molbio Diagnostics IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO is currently subscribed 27.68x, indicating strong demand across investor categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 23,25,146 |
17,43,860
11,62,574
5,81,286
|
40,69,005 | 81,58,531 |
|
Day 1
10-08-26 05:00 PM
|
1.00 x |
0.73x
0.70x
0.80x
|
0.77 x | 0.83 x |
|
Day 2
11-08-26 05:00 PM
|
1.39 x |
5.21x
4.31x
7.01x
|
3.18 x | 3.11 x |
Molbio Diagnostics Valuations
Earnings
- EPS Pre IPO
- ₹14.56/-
- EPS Post IPO
- ₹14.24/-
- P/E Pre IPO
- 55.43
- P/E Post IPO
- 56.67
Returns
- ROE
- 15.59%
- ROCE
- 17.55%
- RoNW
- 14.55%
- PAT Margin
- 11.28%
Fundamentals
- Price / Book
- 9.55
- Market Cap
- ₹9,299.87 Cr.
Molbio Diagnostics Financials( In Crs.)
| 31-Mar-26 | 31-Mar-25 | 31-Mar-24 | |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Revenue | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves & Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Molbio Diagnostics Company & Offer Insights
About Molbio Diagnostics
Incorporated in October 2000, Molbio Diagnostics Limited is an international POC (Point of Care) molecular diagnostics company providing the research, development, manufacture, and marketing of rapid diagnostic tools for various infectious and non-communicable diseases. The company owns proprietary 'Truenat' platform – it is a portable, battery-driven PCR-based molecular diagnostics system that produces reliable tests in an hour.
Molbio provides molecular diagnostics solutions for more than 30 diseases through 43 diagnostic tests that include tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. Besides, the company also provides radiology, digital pathology, and breast health screening services through its subsidiaries and strategic partnerships while continuously broadening the diagnostics products range through advanced R&D operations.
There are six manufacturing sites of Molbio located in India and the company provides its products to over 90 countries worldwide through government health programs, diagnostic laboratories, hospitals, and other international healthcare companies. Supported with its patent portfolio, international certification, and strategic acquisitions, Molbio is recognized as the leader in innovations in molecular diagnostics.
As of March 31, 2026, Molbio had 1,225 employees on permanent positions in research and development, manufacturing, quality control, sales, financial, and corporate departments.
Molbio Diagnostics Promoter(s)
Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Sriram Natarajan are the company's promoters of Molbio Diagnostics.
Molbio Diagnostics IPO Issue Objectives
- •
- Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space.
- •
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
- •
- General corporate purposes
Molbio Diagnostics IPO - Anchor Investors
Molbio Diagnostics Limited finalised its anchor investor allocation on August 7, 2026, raising ₹281.46 crore from 33 institutional investors at an anchor price of ₹807 per share.
The anchor book comprises 34,87,717 equity shares allocated across domestic mutual funds, life insurance companies, and foreign portfolio investors. Domestic mutual funds received 67.51% of the anchor allocation through 9 fund houses across 19 schemes, including HDFC Mutual Fund, Kotak Mahindra Mutual Fund, ICICI Prudential Mutual Fund, Nippon India Mutual Fund, Mirae Asset Mutual Fund, WhiteOak Capital Mutual Fund, Motilal Oswal Mutual Fund, Tata Mutual Fund, and Edelweiss Mutual Fund. Life insurance companies received 7.62% of the allocation, comprising Bajaj Life Insurance Limited, Axis Max Life Insurance Limited (across 8 fund/pension schemes), and HDFC Life Insurance Company Limited.
Leading foreign portfolio investors include Goldman Sachs Funds at 8.88%, International Finance Corporation at 7.11%, BlackRock Global Funds – India Fund at 7.11%, and Goldman Sachs ETF Trust at 1.78%.
Molbio Diagnostics IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Molbio Diagnostics | N/A | N/A | 14.55% | 1445 |
| Poly Medicure | N/A | 52.61 | 10.37% | 1875 |
| Dr. Lal Pathlabs | N/A | 62.20 | 20.78% | 2762 |
| Metropolis Healthcare | N/A | 63.72 | 12.56% | 1645 |
| Vijaya Diagnostic | N/A | 81.02 | 18.07% | 814 |
Molbio Diagnostics IPO - Strengths and Risks
Molbio Diagnostics IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Molbio Diagnostics
+91 8326724888
investors@molbiodiagnostics.com
http://www.molbiodiagnostics.com/
Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
Registrar Contact Details
Frequently Asked Questions
Click any question to reveal the answer
Molbio Diagnostics IPO is a book-built IPO worth ₹939.7 crore. The price band is ₹768–₹807 per share. The IPO opens on Aug 10, 2026 and closes on Aug 12, 2026. It will be listed on BSE and NSE. Kfin Technologies Ltd. is the registrar.
The price band of Molbio Diagnostics IPO is ₹768 to ₹807 per share.
The lot size of Molbio Diagnostics IPO is 18 shares.
The minimum investment for Molbio Diagnostics IPO is approximately ₹14,526 based on the upper price band .
Molbio Diagnostics IPO opens on Aug 10, 2026 and closes on Aug 12, 2026.
The allotment date of Molbio Diagnostics IPO is Aug 13, 2026.
Molbio Diagnostics IPO is expected to be listed on Aug 17, 2026, on BSE and NSE .
Molbio Diagnostics IPO GMP today is ₹134 per share (a 17% premium over the ₹807 upper price band) as of 12 Aug 2026, 1:30 PM IST. The indicative listing price is ₹941 (₹807 upper price band + ₹134 GMP). GMP fell ₹7 from the previous recorded quote.
Molbio Diagnostics IPO valuation snapshot: P/E 56.67, EPS ₹14.24/-, P/B 9.55, RoNW 14.55%, and market cap ₹9,299.87 Cr.
To apply for Molbio Diagnostics IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Molbio Diagnostics IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Molbio Diagnostics IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Molbio Diagnostics IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Molbio Diagnostics IPO allotment status on IPO Ji for quick and easy access.
|
Offer Date |
Aug 10 - Aug 12, 2026 |
|
Offer Price |
₹ 768-807 |
|
Lot Size |
18 |
Please login to Apply IPO